This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Petrik, D. Articles by Le, Q.-T. Search for Related Content PubMed PubMed Citation Articles by Petrik, D. Articles by Le, Q.-T. Social Bookmarking                            What's this?

Plasma Osteopontin Is an Independent Prognostic Marker for Head and Neck Cancers

David Petrik, Philip W. Lavori, Hongbin Cao, Yonghua Zhu, Priscilla Wong, Erin Christofferson, Michael J. Kaplan, Harlan A. Pinto, Patrick Sutphin, Albert C. Koong, Amato J. Giaccia, Quynh-Thu Le

From the Department of Radiation Oncology; Department of Health Research and Policy, Division of Biostatistics; Department of Otolaryngology-Head and Neck Surgery; Department of Medicine, Division of Oncology, Stanford University; and the Palo Alto Health Care System, Palo Alto, CA

Address reprint requests to Quynh-Thu Le, MD, Department of Radiation Oncology, 875 Blake Wilbur Dr, MC 5847, Stanford, CA 94305-5847; e-mail: qle{at}stanford.edu

Purpose To confirm the relationship between plasma osteopontin (OPN) levels and treatment outcomes in head and neck squamous cell carcinoma (HNSCC) patients in an expanded study.

Patients and Methods One hundred forty patients with newly diagnosed HNSCC were enrolled onto this study, 54 previously reported and 86 new patients. Pretreatment plasma OPN levels were assessed in all patients by an enzyme-linked immunosorbent assay method. OPN levels were correlated to treatment outcomes in the new group of patients. Detailed analyses were also performed on the relationship between OPN and tumor control rate, event-free survival (EFS), and postrelapse survival for the entire group.

Results Using a previously defined cut off point of 450 ng/mL, there was a significant correlation between OPN and freedom-from-relapse (P = .047), overall survival (P = .019), and EFS (P = .023) in the new, independent patient cohort (n = 86). Sequence of event analyses using the entire group (N = 140) revealed that OPN was an independent prognostic factor for initial tumor control, EFS in those who have achieved tumor control, and postrelapse survival.

Conclusion In this expanded study, we were able to replicate the prognostic significance of OPN using a predefined cut off point in an independent patient group and demonstrated that plasma OPN is an independent prognostic marker for HNSCC.

Supported by United States Public Health Service Grant No. CA-67166 (Q-T.L., P.W., H.C., and A.J.G.), the Damon Runyon-Lilly Clinical Investigator Award (A.C.K.), and the Henry Kaplan Research Fellowship (D.P.).

Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL May 13-17, 2005.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Jain, D. A. McKnight, L. W. Fisher, E. B. Humphreys, L. A. Mangold, A. W. Partin, and N. S. Fedarko Small Integrin-Binding Proteins as Serum Markers for Prostate Cancer Detection Clin. Cancer Res., August 15, 2009; 15(16): 5199 - 5207. [Abstract] [Full Text] [PDF]

				I. Snitcovsky, G. M. Leitao, F. S. Pasini, K. C. S. Brunialti, F. R. R. Mangone, S. Maistro, G. de Castro Jr, R. C. Villar, and M. H. H. Federico Plasma Osteopontin Levels in Patients With Head and Neck Cancer Undergoing Chemoradiotherapy Arch Otolaryngol Head Neck Surg, August 1, 2009; 135(8): 807 - 811. [Abstract] [Full Text] [PDF]

				P. H. Anborgh, S. M. Wilson, A. B. Tuck, E. Winquist, N. Schmidt, R. Hart, S. Kon, M. Maeda, T. Uede, L. W. Stitt, et al. New Dual Monoclonal ELISA for Measuring Plasma Osteopontin as a Biomarker Associated with Survival in Prostate Cancer: Clinical Validation and Comparison of Multiple ELISAs Clin. Chem., May 1, 2009; 55(5): 895 - 903. [Abstract] [Full Text] [PDF]

				E. P. Hui, F. L. Sung, B. K.H. Yu, C. S.C. Wong, B. B.Y. Ma, X. Lin, A. Chan, W.-l. Wong, and A. T.C. Chan Plasma Osteopontin, Hypoxia, and Response to Radiotherapy in Nasopharyngeal Cancer Clin. Cancer Res., November 1, 2008; 14(21): 7080 - 7087. [Abstract] [Full Text] [PDF]

				P. C. Mack, M. W. Redman, K. Chansky, S. K. Williamson, N. C. Farneth, P. N. Lara Jr, W. A. Franklin, Q.-T. Le, J. J. Crowley, and D. R. Gandara Lower Osteopontin Plasma Levels Are Associated With Superior Outcomes in Advanced Non-Small-Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy: SWOG Study S0003 J. Clin. Oncol., October 10, 2008; 26(29): 4771 - 4776. [Abstract] [Full Text] [PDF]